Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from cl...
Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143
About this item
Full title
Author / Creator
Publisher
Switzerland: International AIDS Society
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: International AIDS Society
Subjects
More information
Scope and Contents
Contents
Introduction
NEAT001/ANRS143 was an open‐label, randomized, non‐inferiority study comparing raltegravir+darunavir/r(RGV+DRV/r) vs. tenofovir/emtricitabine+darunavir/r (TDF/FTC+DRV/r) in HIV‐infected antiretroviral naïve adults. Primary efficacy outcome was a composite of virological and clinical events by week 96.
Materials and Methods
Cli...
Alternative Titles
Full title
Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4224823
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4224823
Other Identifiers
ISSN
1758-2652
E-ISSN
1758-2652
DOI
10.7448/IAS.17.4.19572
